Sharekhan

Solara Active Pharma Sciences Ltd

Mon 6/04/2026,15:58:17 | NSE : SOLARA

₹ 470.55-5.55 (-1.17%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 490.00

Previous Close

₹ 476.10

Volume

77915

Mkt Cap ( Rs. Cr)

₹2093.43

High

₹ 490.00

Low

₹ 458.55

52 Week High

₹ 734.40

52 Week Low

₹ 422.00

Book Value Per Share

₹ 278.13

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Solara Active Pharma Sciences Ltd

Your Vote -

Buy

88.24%

Hold

5.29%

Sell

6.47%

88.24%

170 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

470.55

20

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

20

Option Chain

Analyzes market sentiment, predicts Solara Active Pharma Sciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Solara Active Pharma - Suspension of Trading

    30 Mar 2026, 8:06PM Members of the Exchange are hereby informed that the trading in the partly paid-up equity shares (Series: E1, ISIN: IN9624Z01022) of Solara Active Pha

  • Solara Active Pharma - Trading Window

    26 Mar 2026, 4:07PM Solara Active Pharma Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)

  • Solara Active Pharma - Copy of Newspaper Publication

    25 Mar 2026, 3:08PM SOLARA: Solara Active Pharma Sciences Limited has informed the Exchange about Copy of Newspaper Publication with respect to Record date intimation for

  • Solara Active Pharma - Copy of Newspaper Publication

    25 Mar 2026, 2:57PM Newspaper advertisement published regarding the Special window for Re-lodgement of Transfer Requests of Physical shares by the Shareholders.

  • Solara Active Pharma - General Update - Rights Issue - Second & Final Call

    24 Mar 2026, 10:44AM Solara Active Pharma Sciences Limited has informed the exchange that the Rights Issue Committee members at its meeting held on March 24, 2026, has app

  • Solara Active Pharma - General Updates

    24 Mar 2026, 10:38AM Solara Active Pharma Sciences Limited has informed the Exchange that the Rights issue committee members at its meeting held on March 24, 2026, has app

  • Solara Active Pharma - Corporate Action- Record Date For The Purpose Of Making Second And Final Call For Rights Equity Shares

    24 Mar 2026, 10:29AM Solara Active Pharma Sciences Limited has fixed April 02, 2026, as the record date for the purpose of making second and final call for the shares issu

  • Solara Active Pharma - Record Date

    24 Mar 2026, 10:25AM Solara Active Pharma Sciences Limited has fixed April 02, 2026 as the Record date for the purpose of making Second and Final call for the shares issue

  • Solara Active Pharma - Committee Meeting Updates

    24 Mar 2026, 10:20AM Solara Active Pharma Sciences Limited has informed the Exchange that the Rights issue committee members at its meeting held on March 24, 2026, has app

  • Solara Active Pharma - Board Meeting Outcome for Outcome Of The Rights Issue Committee Meeting

    24 Mar 2026, 10:20AM Solara Active Pharma Sciences Limited has informed the Exchange that the Rights issue committee members at its meeting held on March 24, 2026, has app

  • Solara Active Pharma - Board Meeting Intimation for Prior Intimation Of Meeting Of Rights Issue Committee

    19 Mar 2026, 5:46PM Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/03/2026 ,inter alia, to

  • Solara Active Pharma - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

    18 Mar 2026, 7:02PM Solara Active Pharma Sciences Limited has informed the Exchange about the receipt of Demand Notice from the Income Tax Authorities.

  • Solara Active Pharma - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulatio

    18 Mar 2026, 7:00PM Solara Active Pharma Sciences Limited has informed the exchange about the receipt of Demand Notice from the Income Tax Authorities

  • Solara Active Pharma - Shareholders meeting

    10 Mar 2026, 1:02PM SOLARA: Solara Active Pharma Sciences Limited has submitted the Exchange a copy of the Scrutinizer's Report of Postal Ballot. Further, the Company has

  • Solara Active Pharma - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

    10 Mar 2026, 12:54PM Solara Active Pharma Sciences Limited has informed the Exchange the Voting Results alongwith the Scrutinizer's Report with respect to the Postal Ballo

  • Solara Active Pharma - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

    10 Mar 2026, 12:50PM Solara Active Pharma Sciences Limited has submitted to the exchange a copy of the Scrutinizer's Report and the Voting Results in respect of the Postal

  • Solara Active Pharma - General Updates

    4 Mar 2026, 6:52PM Solara Active Pharma Sciences Limited has informed the Exchange regarding Receipt of call money pursuant to the Second Reminder Notice issued for paym

  • Solara Active Pharma - Receipt Of Call Money Pursuant To The Second Reminder Notice Issued For Payment Of First Call Money On

    4 Mar 2026, 6:40PM Solara Active Pharma Sciences Limited has informed the exchange regarding the receipt of first call money pursuant to the second reminder Notice

  • Solara Active Pharma - General Updates

    4 Mar 2026, 5:01PM SOLARA: Intimation regarding the closure of wholly owned subsidiary of the Company in Brazil.

  • Solara Active Pharma - Intimation Regarding The Closure Of Wholly Owned Subsidiary Of The Company In Brazil.

    4 Mar 2026, 4:37PM Intimation regarding the closure of wholly owned subsidiary of the Company in Brazil.

  • Solara Active Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Feb 2026, 5:52PM Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Com

  • Solara Active Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    10 Feb 2026, 5:49PM Transcript of earnings call pertaining to unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025.

  • Solara Active Pharma - Copy of Newspaper Publication

    7 Feb 2026, 4:34PM Newspaper publication on February 07, 2026, with respect to the unaudited financial results for the quarter and nine months ended December 31, 2025

  • Solara Active Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    6 Feb 2026, 6:51PM Solara Active Pharma Sciences Limited has intimated the Exchange about the Audio Recording of the Q3 FY26 Earnings Call held on February 06, 2026.

  • Solara Active Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    6 Feb 2026, 6:48PM Solara Active Pharma Sciences Limited has intimated the Exchange about the Audio Recording of the Q3 FY26 Earnings Call held on February 06, 2026.

  • Solara Active Pharma - Monitoring Agency Report

    6 Feb 2026, 6:35PM Monitoring Agency Report for the quarter ended December 31, 2025

  • Solara Active Pharma - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    6 Feb 2026, 6:34PM Monitoring Agency Report for the quarter ended December 31, 2025

  • Solara Active Pharma - Copy of Newspaper Publication

    6 Feb 2026, 3:54PM Solara Active Pharma Sciences Limited has informed the Exchange about Copy of Newspaper Publication with respect to Second reminder for payment of the

  • Solara Active Pharma posts Q3 net loss of Rs 17.42 cr

    6 Feb 2026, 2:40PM The company reported standalone net loss during the quarter stood at Rs 17.42 crore compared to net profit of Rs 8.10 crore in the previous year quart

  • Solara Active Pharma - Statement of deviation(s) or variation(s) under Reg. 32

    6 Feb 2026, 2:38PM Solara Active Pharma Sciences Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32

  • Solara Active Pharma - Statement Of Deviation And Variation For Funds Raised Under Rights Issue For The Quarter Ended Decembe

    6 Feb 2026, 2:37PM Solara Active Pharma Sciences Limited has informed the exchange that there is no Deviation and Variation in funds raised through Rights issue for the

  • Solara Active Pharma - Announcement Under Regulation 30 Of SEBI (LODR), 2015 Regarding The Revision And Adoption Of Policies.

    6 Feb 2026, 2:24PM The Company has reviewed and adopted the revised \ Policy for Determining Materiality of Events/Information for Disclosure to the Stock Exchanges\ and

  • Solara Active Pharma - General Updates

    6 Feb 2026, 2:19PM The Company has reviewed and approved the revised Policy for Determining Materiality of Events / Information for Disclosure to Stock Exchanges and

  • Solara Active Pharma - Press Release

    6 Feb 2026, 2:10PM Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled ""Solara Q3'26 Performance

  • Solara Active Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    6 Feb 2026, 2:08PM Solara Active Pharma Sciences Limited has informed the exchange regarding the Press release dated February 06, 2026 titled \Solara Announces Q3'26 Fin

  • Solara Active Pharma - Board Meeting Outcome for Board Meeting Outcome For Unaudited Financial Results For The Quarter Ended

    6 Feb 2026, 1:51PM Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, the unaudited Standalone and Consolidated Financial Results for

  • Solara Active Pharma - Outcome of Board Meeting

    6 Feb 2026, 1:47PM Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, the unaudited Standalone and Consolidated Financial Results for

  • Solara Active Pharma - Board Meeting Outcome For Unaudited Financial Results For The Quarter Ended December 31, 2025

    6 Feb 2026, 1:47PM Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, the unaudited Standalone and Consolidated Financial Results for

  • Solara Active Pharma - Copy of Newspaper Publication

    5 Feb 2026, 6:32PM Copy of Newspaper Advertisement published with respect to dispatch of the notice of Postal Ballot dated February 04, 2026.

  • Solara Active Pharma - Dispatch Of Second Reminder Notice For Payment Of First Call Money

    4 Feb 2026, 11:10PM Solara Active Pharma Sciences Limited has informed the Exchange about dispatch of Second Reminder Notice for payment of First call under Rights issue.

  • Solara Active Pharma - General Updates

    4 Feb 2026, 11:07PM Solara Active Pharma Sciences Limited has informed the Exchange about dispatch of second reminder Notice for payment of first call under Rights Issue.

  • Solara Active Pharma - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    4 Feb 2026, 10:53PM Solara Active Pharma Sciences Limited has informed the Exchange regarding Notice of Postal Ballot dated February 04, 2026.

  • Solara Active Pharma - Shareholders meeting

    4 Feb 2026, 10:50PM Solara Active Pharma Sciences Limited has informed the Exchange regarding Notice of Postal Ballot dated February 04 2026

  • Solara Active Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    3 Feb 2026, 3:03PM Solara Active Pharma Sciences Limited has informed the Exchange about the revised Intimation of Schedule of Analyst / Institutional Investor call und

  • Solara Active Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    3 Feb 2026, 2:59PM Revised Intimation of Schedule of Analyst / Institutional Investor call under the SEBI (Listing Obligations and Disclosure Requirements), Regulations,

  • Solara Active Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    30 Jan 2026, 8:32PM Solara Active Pharma Sciences Limited has informed the Exchange about the Schedule of Investors/Analysts call to be held on Friday, February 06, 2026

  • Solara Active Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    30 Jan 2026, 8:28PM Solara Active Pharma Sciences Limited has informed the Exchange about the Schedule of Investors/Analysts call to be held on Friday, February 06, 2026

  • Solara Active Pharma - Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended December 31

    30 Jan 2026, 7:34PM Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to

  • Solara Active Pharma has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2025

    20 Jan 2026, 3:51PM As of December 2025, 42.00% is owned by Indian Promoters and 58.00% by Public. <p align=justify> Top five Promoters holding highest number of shares o

  • Solara Active Pharma - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    12 Jan 2026, 3:42PM Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025

  • Solara Active Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    12 Jan 2026, 3:31PM Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025.

  • Solara Active Pharma

    6 Jul 2023 , 10:51AM Solara Active Pharma has agreed to raise funds through the issue of equity shares of FV of Rs. 10 not exceeding Rs. 450 Cr. by the way of rights issue to eligible equity shareholder of the company. We do not have coverage on it.

  • Solara Active Pharma successfully completes EU GMP Inspection

    13 Feb 2023 , 12:14PM Completion of the EU-GMP inspection at the Cuddalore facility of the Company

  • Stock Update: Solara Active Pharma Science

    12 Nov 2021 , 11:50AM Stock Update: Solara Active Pharma Science Q2FY22 Results Update

  • Solara Active Pharma Sciences Q2Fy22 results

    11 Nov 2021 , 5:14PM Solara Active Pharma Sciences Q2Fy22 results – Weak quarter, results missed estimates

  • Solara Active Pharma Sciences: Q1FY22 Results update

    5 Aug 2021 , 10:59AM Solara Active Pharma Sciences Ltd: Q1FY22 Results update - Healthy quarter; Robust outlook

  • Solara Active Pharma Sciences Q1FY2022

    4 Aug 2021 , 3:31PM Solara Active Pharma Sciences Q1FY2022: Healthy quarter; results miss estimates

  • Solara announces CEP for Ranitidine Hydrochloride drug substance restored by EDQM

    2 Jul 2021 , 3:31PM Solara is the first company to have its CEP restored among Ranitidine API manufacturers

  • Solara Active Pharma Sciences

    2 Jul 2021 , 3:19PM Solara Active Pharma Sciences: Has announced that the EDQM ( European Directorate for the Quality of Medicines & HealthCare) has restored is CEP for Ranitidine Hydrochloride drug substance (API). Solara had put in place robust manufacturing and quality processes to mitigate the risks of N-Nitroso Dimethylamine (NDMA) formation in the Ranitidine HCL API and subsequent submission of the pertinent data has fast-tracked the restoration of CEP by EDQM. Solara is the only company to have its CEP for Ranitidine hydrochloride restored, hence positive

  • Solara Active Pharma Sciences

    1 Jun 2021 , 10:27AM The government of India has given approval to four waitlisted firms under the Production Linked Incentive (PLI) scheme for domestic manufacturing of bulk drugs. It envisages setting up greenfield plants in four different target segments with a total outlay of Rs 6,940 crore for the period 2020-21 to 2029-30.Now the Government has approved the application of 4 wait listed players who were eligible under the scheme. These include Solara Active Pharma Sciences, while the other companies being approved are Rajasthan Antibiotics Ltd, Dhatri Lab Pvt Ltd and Vital Laboratories Pvt Ltd. The products for which the approvals have been given are 1 Cyclohexane Diacetic Acid, Meropenem, Ritonavir and Levofloxacin. The receipt of the approval for PLI scheme is positive for Solara Active Pharma Sciences.

  • Solara Active Pharma Sciences: Q4FY2021 Result Update

    7 May 2021 , 11:10AM Solara Active Pharma Sciences: Q4FY2021 Result Update - Strong quarter; Robust outlook

  • Stock update - Solara Active Pharma Sciences

    13 Apr 2021 , 11:03AM Stock update - Solara Active Pharma Sciences : Synergetic Merger, Earnings accretive

  • Solara Active Pharma Sciences board approves merger of Aurore Life sciences

    12 Apr 2021 , 12:12PM Solara Active, Aurore Life combine to create second largest Pure Play API / CRAMs company in India

  • Solara Active Pharma Sciences

    12 Apr 2021 , 10:18AM Solara Active Pharma Sciences (Solara): Board approves merger of Aurore Life sciences in an all-stock deal; combined entity to be pure play API company of scale with strong presence in key markets, broad product portfolio and could strengthen Solara’s CRAMS business. We believe the merger would be positive as both the business are synergistic and would open up multiple growth avenues and enable to achieve operational efficiencies

  • Solara Active Pharma Sciences

    19 Feb 2021 , 9:09AM As per media news, The promoters along with TPG capital are said to be looking for an exit from the company. The total promoters stake stands at 44% while TPG Group had a stake of around 15%. The stake sale is likely to trigger an open offer.

  • Solara Active Pharma Sciences : Stock Update

    9 Dec 2020 , 12:04PM Solara Active Pharma Sciences : Stock Update – Growth Levers Intact

  • Solara Active Pharma announces interim dividend

    11 Nov 2020 , 12:20PM Solara Active Pharma Sciences board declares interim dividend of Rs. 4

  • Solara Active Pharma reports good Q2 earnings

    30 Oct 2020 , 3:12PM Solara Active Pharma: Strong operating performance leads to PAT beat

  • Solara Active Pharma Sciences

    16 Sep 2020 , 10:08AM Promoters Pronomz Ventures released pledge of 13.18 lakh shares on September 10, 2020. Post the release the proportion of pledged shares stands at 4.7% of the total promoters holdings down from 13%. The release of the pledged shares is positive

  • New Idea - Solara Active Pharma Sciences

    14 Sep 2020 , 11:40AM New Idea - Solara Active Pharma Sciences – Viewpoint - Well placed to harness API opportunities

  • Solara Active Pharma completes USFDA inspection at SRC

    17 Dec 2018 , 11:35AM Solara Research Centre (SRC) completes USFDA Inspection with Zero 483s
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Solara Active Pharma Sciences Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 1872.27 1936.8 2504.28 2551.62 2108.49
Liabilities 1872.27 1936.8 2504.28 2551.62 2108.49
Equity 40.25 36 36 36 35.92
Gross Profit 203.84 -95.06 134.04 80.35 385.33
Net Profit -1.08 -566.87 -22.21 -58.56 220.96
Cash From Operating Activities 212.8 110.95 156.17 -241.77 154.44
NPM(%) -0.08 -43.98 -1.53 -4.61 13.66
Revenue 1283.76 1288.92 1443.81 1268.34 1616.88
Expenses 1079.92 1383.98 1309.77 1187.99 1231.55
ROE(%) -0.08 -45.81 -1.79 -4.73 17.85

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
18 Aug 2021 3 30 0 1648.75
19 Nov 2020 4 40 0 1095.5
28 Jul 2020 2 20 0 502.4
06 Aug 2019 5 50 0 442.1

Peers

Other companies within the same industry or sector that are comparable to Solara Active Pharma Sciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 650.10 -0.69 38.60 268.32 301.39 0.77
Lotus Eye Hospital and Institute Ltd 104.43 1.87 336.87 977.74 3.55 0.00
Vaishali Pharma Ltd 5.85 -2.17 0.00 6133.68 3.13 0.00
Astec Lifesciences Ltd 545.20 0.41 0.00 922.03 -604.75 0.00

Company Info

Our Company was originally incorporated on February 23, 2017 under the Companies Act, 2013 as SSL Pharma Sciences Limited with the RoC. The name of the Company was changed to Solara Active Pharma Sciences Limited and a fresh certificate of incorporation was issued by the RoC on March 25, 2017. 2019 -Solara Active Pharma Sciences Limited said that, "it has successfully completed the US FDA inspection at the multi-product manufacturing facility at Cuddalore with ZERO 483s i 2021 -Solara Active Pharma approves acquisition of balance 10.77% stake in Sequent Penems 2023 -Solara Active Pharma Sciences completes WHO inspection at its Cuddalore facility. 2024 -The company issued rights shares of Rs. 10 in the ratio of 1:3 at a premium of Rs. 365 per share.

Our Company was originally incorporated on February 23, 2017 under the Companies Act, 2013 as SSL Pharma Sciences Limited with the RoC. The name of the Company was changed to Solara Active Pharma Sciences Limited and a fresh certificate of incorporation was issued by the RoC on March 25, 2017. 2019 -Solara Active Pharma Sciences Limited said that, "it has successfully completed the US FDA inspection at the multi-product manufacturing facility at Cuddalore with ZERO 483s i 2021 -Solara Active Pharma approves acquisition of balance 10.77% stake in Sequent Penems 2023 -Solara Active Pharma Sciences completes WHO inspection at its Cuddalore facility. 2024 -The company issued rights shares of Rs. 10 in the ratio of 1:3 at a premium of Rs. 365 per share.

Parent Organisation

Solara Active Pharma Sciences Ltd.

Founded

23/02/2017

Managing Director

Mr.Sandeep Shashikantha Rao

NSE Symbol

SOLARAEQ

FAQ

OPEN FREE* DEMAT ACCOUNT